Stockwinners Market Radar for May 01, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:51 EDT Conx announces closing of initial business combination - CONX Corp completed its previously announced transaction pursuant to the terms of the purchase and sale agreement dated as of March 10, 2024, by and between the Company and EchoStar Real Estate Holding L.L.C. a subsidiary of EchoStar Corporation. Pursuant to the terms of the Purchase Agreement, the Company purchased from Seller the commercial real estate property in Littleton, Colorado, comprising the corporate headquarters of DISH Wireless, for a purchase price of $26.75 million. The Transaction constitutes the Company's initial business combination. In connection with the Transaction, the Company and Seller have entered into a sale-leaseback agreement, pursuant to which Seller will lease back the Property from the Company.

19:06 EDT Patterson-UTI sees U.S. Contract Drilling operating average of 114 rigs in Q2 - The company said, "We see steady drilling and completion activity in oil basins, with the expectation that a few operators may add drilling rigs later this year based on current oil prices. Our activity in natural gas basins has so far been more resilient than we previously anticipated, although we have continued to see some activity decline in the second quarter. We currently expect our activity in natural gas basins will remain steady with second quarter levels through year-end. Within the Drilling Services segment, we expect U.S. Contract Drilling to operate an average of 114 U.S. rigs in the second quarter, with adjusted gross profit per operating day down roughly $300 from the prior quarter. Aside from U.S. Contract Drilling, we expect other Drilling Services adjusted gross profit will be down slightly in the second quarter compared to the prior quarter. Completion Services activity has declined slightly to start the second quarter, mostly in the natural gas basins where our customers continue to slow activity in response to current natural gas prices. We also expect to see a few dedicated fleets operate in the second quarter with planned gaps in the schedule. Completion Services revenue for the second quarter is expected to be approximately $860 million, with approximately $690 million in direct operating costs and an adjusted gross profit of around $170 million. We expect an improvement in activity in the third quarter as our dedicated and long-term customers resume completion activity after new pads are drilled. We are continuing our electric fleet deployment and remain on pace to have 140,000 horsepower of electric frac equipment working by mid-2024. Second quarter results in our Drilling Products segment are expected to be relatively in line with the first quarter, as continued growth in our International operations is expected to largely offset seasonal activity declines from Canadian spring breakup. For the second quarter, Other revenue and adjusted gross profit is expected to be roughly flat with the first quarter. For the second quarter, we expect selling, general and administrative expense of approximately $65 million, and depreciation, depletion, amortization, and impairment expense of approximately $265 million."

17:18 EDT IAC to replace American Equity in S&P 600 at open on 5/6 - Brookfield Reinsurance (BNRE) is acquiring American Equity Investment Life Holding Company (AEL) in a deal expected to be completed prior to the open on May 3.

17:13 EDT Boeing awarded $457.69M Navy contract modification - Boeing was awarded a $457.69M modification to a previously awarded cost-plus-fixed-fee, cost-plus-incentive-fee, indefinite-delivery/indefinite-quantity contract. This modification exercises an option that increases the contract ceiling to provide additional aircraft inductions, continued non-recurring engineering, systems engineering and program management support to extend service life from 6,000 flight hours to 10,000 flight hours and incorporate Block III avionics capabilities for 29 F/A-18 Block II Super Hornets. Work is expected to be completed in June 2026. No funds will be obligated at the time of award; funds will be obligated on individual orders as they are issued. Naval Air Systems Command is the contracting activity.

17:08 EDT Summit Hotel Properties increaes dividend 33% to 8c per share - Summit Hotel Properties declared a 33% increase to its quarterly cash dividend rate to 8c per share on its common stock and per common unit of limited partnership interest in Summit Hotel OP, LP. The quarterly dividend of 8c per share represents an annualized dividend yield of 5.3%.

17:05 EDT Boots Capital calls for change to Crown Castle board - Boots Capital, an investment vehicle led by Ted Miller, co-founder and former CEO of Crown Castle, released a presentation highlighting why change to Crown Castle's Board of Directors is "urgently needed," and detailing how Boots Capital's four nominees, Ted B. Miller, Charles C. Green, David P. Wheeler, and Tripp H. Rice, have "the right leadership skills, operating plan, and corporate governance track record to restore value for shareholders and all stakeholders." Miller stated: "Crown Castle's Board has no one to blame other than themselves for allowing the Company to pursue a fiber acquisition strategy that has cost shareholders more than $22 billion, for failing to have a proper CEO succession strategy in place, and for presiding over significant relative Total Shareholder Return (TSR) underperformance over 1-, 3-, 5-, 7-, and 10-year periods. Yet, Crown Castle would rather waste substantial additional shareholder resources on a proxy contest and ask for even more time in support of the same directors who have failed so spectacularly for more than a decade. If elected, Boots Capital's nominees will give the Crown Castle Board the tools, skills, and a fresh, experienced view for the major turnaround that will benefit all shareholders. We believe that our expertise and plan - finalizing the fiber sale, refocusing the Company on tower efficiency and growth, resetting compensation plans, reviving customer relationships, rebuilding shareholder trust, and invigorating employees - will help reboot Crown Castle and drive significant, long-term value creation."

17:03 EDT Southwest announces leadership updates - Southwest announced that EVP & Chief Legal & Regulatory Officer & Corporate Secretary Mark Shaw has decided to move to an Executive Advisor role, effective June 1. Shaw joined Southwest nearly 24 years ago. With Shaw's transition, SVP & Chief Corporate Affairs Officer Jason Van Eaton is promoted to EVP, Chief Regulatory & Corporate Affairs Officer, effective June 1. In this role, Van Eaton's duties will include legislative and regulatory policy oversight, airline airport relationships management, facility construction and maintenance, corporate security, and real estate planning. He'll oversee the Company's Airport Affairs, Facilities, Governmental Affairs, Legal, and Real Estate Departments. Van Eaton joined Southwest in May 2015 and was named SVP & Chief Corporate Affairs Officer in 2018. Before landing at Southwest, he held positions in the U.S. Senate for 13 years before founding a consulting services company he managed for eight years. Additionally, VP Legal-Corporate & Transactions Jeff Novota is promoted to VP General Counsel & Corporate Secretary, effective June 1. Before joining Southwest in 2011, Novota was a practicing attorney at a Chicago law firm.

17:02 EDT Metagenomi regains full development rights to RIGS systems - Metagenomi announced it has regained full global rights to research, develop, manufacture, and commercialize its wholly-owned gene editing technologies, including base editors and RNA-mediated integration systems which were previously subject to exclusive rights granted to Moderna, Inc. Metagenomi and Moderna have mutually agreed to terminate their collaboration on primary hyperoxaluria type 1 and rights to develop the PH1 program, as well as all other rights granted under the collaboration, will be returned as part of the termination. "We are pleased to regain full control of the development of base editing technology and RIGS systems so that we may advance them in areas of significant need, such as Alpha-1 antitrypsin deficiency and Wilson's disease," said Brian C. Thomas, Ph.D., Chief Executive Officer & Founder, Metagenomi, Inc. Moderna's involvement in the collaboration, which includes the PH1 program, ended in conjunction with a strategic prioritization by the company. Moderna remains a Metagenomi shareholder. This announcement represents a renewed opportunity to advance curative genetic medicine through the translation of Metagenomi's broad toolbox of wholly-owned gene editing technologies, as well as a broadened ability to engage with partners in target-specific application of these technologies.

16:59 EDT Schrodinger sees Q2 software revenue $31M-$33M vs. $33.4M in Q1

16:57 EDT National Bank increases quarterly dividend 3.7% to 28c per share - National Bank announced that its board of directors approved a cash dividend to shareholders. The quarterly cash dividend will increase 3.7% from 27c to 28c per share of common stock. The dividend will be payable on June 14 to shareholders of record at the close of business on May 31.

16:55 EDT Pool boosts share repurchase to $600M, increases dividend 9% to $1.20 per share - Pool announced hat its Board of Directors has authorized an increase in the company's share repurchase program to $600M . As of May 1 this adds $316.2M to the $283.8M remaining under its existing share repurchase program for the purchase of the company's common stock in the open market at prevailing market prices. The share repurchase program will continue until otherwise modified or terminated by the Board at any time in its sole discretion. The company also announced that the Board has declared a quarterly cash dividend of $1.20 per share, a 9% increase over the previous quarterly dividend amount of $1.10 per share. The dividend is payable on May 30, to stockholders of record on May 16... As of April 30, there were 38,329,420 shares of common stock outstanding.

16:53 EDT CNH Industrial to change trading symbol on NYSE - CNH Industrial announced that the company's common shares listed on the NYSE will begin trading under the symbol (CNH) effective Monday, May 20.

16:50 EDT FB Financial raises quarterly dividend to 17c per share - FB Financial announced that its board of directors declared a quarterly cash dividend of 17c per share. The dividend is payable on May 28, 2024, to shareholders of record as of May 14, 2024. Christopher T. Holmes, President and Chief Executive Officer, commented, "Today, I am proud to announce the Board has once again approved our quarterly dividend, marking an incredible milestone of 25 consecutive quarters of dividend payments. This achievement reflects our unwavering commitment to delivering value to our shareholders and underscores the strength and consistency of our financial performance. We remain dedicated to our mission of providing sustainable returns and driving long-term shareholder value."

16:46 EDT Elevai Labs announces CCO Kraneiss and CMO Buechler to transition from roles - In conjunction with the reorganization of its skincare operations, Elevai Skincare's Chris Kraneiss, Chief Commercial Officer CCO of Elevai, and Brenda Buechler, Chief Marketing Officer, will transition from their roles from Elevai Labs to oversee operations within Elevai Skincare. This strategic realignment aims to drive operational efficiency and accelerate revenue growth within the skincare segment.."There is a large unmet need of under-developed biotechnology assets we can look at to build a robust pipeline targeting multi-billion-dollar indications, starting with our clinical-stage lead asset in the obesity space," said Deniel Mero, co-founder of Elevai Biosciences. "We look forward to unlocking the potential of EL-22 as a combination with weight loss treatments including GLP-1 receptor agonists, as we embark on the path to building an industry-leading aesthetic medicine company. I'm excited to be working under the Elevai Labs umbrella as co-founder of Elevai Biosciences and executing our future plan to develop and license additional assets, broadening Elevai's existing expertise in aesthetics."

16:42 EDT Emergent BioSolutions announces workforce reduction, closure of two facilities - Emergent BioSolutions announced the next phase of its new operational plan that consolidates operations, closes several manufacturing facilities, and restructures its enterprise workforce. Emergent will continue to focus on its core products business - medical countermeasures and Narcan Nasal Spray -and on delivering for its patients and customers, including the U.S. and allied governments. These strategic actions will lead to a reduction of approximately 300 employees across all areas of the company, and the elimination of approximately 85 positions that are currently vacant. In combination with other rationalizing initiatives, these actions are expected to result in annualized savings of approximately $80M when fully implemented. The costs associated with the restructuring plan are estimated to be approximately $18M-$21M and are expected to be primarily incurred in the second half of 2024. As part of the operational changes, Emergent will shut down both its Baltimore-Bayview Drug Substance manufacturing facility and Rockville, Maryland Drug Product facility. Emergent will concentrate operations at sites in Winnipeg, Canada, and Lansing, Michigan, while the company actively explores strategic alternatives for its other sites throughout the year. As part of the reorganization, a new chief science officer role has been created and added to the executive management team, reporting to Papa.

16:36 EDT UGI Corporation board decides to retain ownership of AmeriGas Propane - After extensive deliberation, the Board has determined that in the current market the best path forward to maximize shareholder value is to retain ownership of AmeriGas Propane. During the review, the company and its financial advisors evaluated several value creation opportunities including a potential sale, spin, and joint venture of AmeriGas. While the company conducted due diligence with multiple strategic and financial parties, the Board decided that the company should focus on a restructuring and operational improvement plan for AmeriGas. The review concluded that disciplined execution of a revised operational strategy and optimization of UGI's diverse mix of strategically located assets best positions the company to create long-term shareholder value. Mario Longhi said, "After a comprehensive review process, the Board agreed that in the current market, the best path forward in creating shareholder value is to execute on its repositioned long-term strategy and strengthen the balance sheet. This includes maintaining an intense focus on customer retention, improved free cash flow generation, effective cost control and disciplined capital allocation. Although the process has concluded, we remain open to all opportunities to optimize our portfolio and unlock further value for shareholders." "For the fiscal year, we are on track to deliver full-year results within our fiscal 2024 adjusted EPS guidance range. We are confident that diligent execution on the fundamentals will enable UGI to build a strong momentum of balanced growth and value creation."

16:33 EDT Marathon Oil reaffirms FY24 guidance - Marathon Oil's originally provided 2024 production, capital expenditure, cost, and tax guidance ranges are all unchanged as the company remains on track to deliver a 2024 program that benchmarks at the top of its peer group on the combination of FCF, capital efficiency, and shareholder returns. The company continues to expect its capital program to be heavily weighted to the first half of the year, with production expected to increase from first quarter levels. At the midpoint of annual guidance, the company expects its $2 billion capital program to deliver 190,000 net bopd, 390,000 net boed, and approximately $2.2 billion of adjusted FCF, assuming $80/bbl WTI, $2.50/MMBtu Henry Hub, and $10/MMBtu TTF. Cash flow sensitivities to WTI, Henry Hub, and TTF commodity prices are provided in the company's first quarter 2024 earnings presentation.

16:30 EDT Sunnova Energy sees FY24 adjusted EBITDA $350M-$450M - The company states: "We are lowering our guidance for customer additions. As Sunnova re-focuses on its core adaptive energy customers it now expects full year 2024 customer additions to fall between 140,000 and 150,000. We are reaffirming our guidance for Adjusted EBITDA, interest income, and principal proceeds from customer notes receivable, net of amounts recorded in revenue, and proceeds from investments in solar receivables. Customer additions between 140,000 and 150,000; Adjusted EBITDA between $350 million and $450 million."

16:29 EDT Summit Materials raises FY24 synergy target to 'at least' $40M

16:27 EDT Freshworks announces Dennis Woodside as CEO, effective May 1 - Freshworks announced the appointment of Dennis Woodside as Freshworks' Chief Executive Officer & President, effective later today. Woodside, currently Freshworks' President, will succeed Girish Mathrubootham, the company's Founder, as CEO. Mathrubootham will transition to a new role of Executive Chairman. Mathrubootham will remain the chairman of the Board of Directors, and Woodside will also remain a member of the Board of Directors. "When I first proposed this next step to the Freshworks Board, we were starting to chart the next phase of our company's journey. We brought Dennis on board to partner with me on crafting an ambitious growth plan, and my hope was that he could eventually lead the team of talented employees around the world to execute it, which would allow me to spend more time on the long-term product vision, innovation and AI strategy," said Mathrubootham. "Dennis has a deep understanding of Freshworks' business, customers and our employees, and a strong track record of building and scaling large global teams - he is the right leader to become our next CEO. I'm thrilled to announce this transition."

16:22 EDT DoorDash down 13% at $111.51 after Q1 earnings miss

16:21 EDT DoorDash sees Q2 Marketplace GOV $19.0B-$19.4B - Sees Q2 adjusted EBITDA $325M-$425M.

16:21 EDT Selective Insurance raises FY24 GAAP combined ratio view to 96.5% from 95.5%

16:20 EDT Monolithic Power sees Q2 revenue $480M-$500M, consensus $474.26M - Sees GAAP gross margin between 55.1% and 55.7%. Non-GAAP gross margin between 55.4% and 56.0%, which excludes the impact from stock-based compensation and related expenses as well as the impact from amortization of acquisition-related intangible assets.

16:18 EDT Barrett Business sees FY24 gross billings 6%-8% - Sees FY24 effective annual tax rate 26%-27%.

16:15 EDT Culp sees Q4 consolidated operating income ($4.7M)-($4.2M) - In addition, the company is updating its previously stated financial outlook for the fourth quarter of fiscal 2024. Due to further weakness in industry demand, the company's consolidated net sales for the fourth quarter are now expected to be approximately 19.0 percent lower as compared to the fourth quarter of fiscal 2023. The company also now expects a consolidated operating loss (loss from operations) for the fourth quarter of fiscal 2024 in the range of $(4.2) million to $(4.7) million. Additionally, the company expects to end the fiscal year with approximately $10.0 million in cash and cash equivalents and no outstanding borrowings. The financial results for the fourth quarter and full fiscal 2024 year will be released on or about June 26, 2024.

16:13 EDT Warrior Met Coal affirms FY24 coal sales 7.4M-8.2M short tons - Affirms FY24: Coal production 7.4M - 8.0M short tons; Cash cost of sales $125 - $135 per short ton; Capital expenditures for existing mines $100M - $110M

16:11 EDT Kemper names director Gerald Laderman chairman, effective immediately - Kemper Corporation announced that its Board of Directors has elected current Director Gerald Laderman to the role of Chairman of the Board, effective immediately. Laderman succeeds Joseph P. Lacher, Jr., who continues as CEO, President and Director. Stuart B. Parker will shift from Lead Director back to Director. Kemper's decision to appoint an independent chairman was previously disclosed in the 2024 Proxy Statement. "Gerry is a well-respected leader that has helped advance Kemper, and I couldn't be more pleased with this appointment," said Lacher. "His strong background, expertise and leadership acumen will further benefit the company as we move to the next chapter of the Kemper story. I look forward to continuing to work alongside Gerry in his new capacity, and know he will serve Kemper well." Laderman joined the Kemper board of directors in February 2020, and has served as a member of the Board's Audit and Investment committees.

16:10 EDT SilverBow Resources sees Q2 production 90.8-95.4 MBoe/d - For the second quarter of 2024, SilverBow expects its production to be 90.8 - 95.4 MBoe/d, with oil volumes of 23.5 - 25.0 MBbls/d. For the full year 2024, the Company increased its production guidance to 90.0 - 97.3 MBoe/d. Based on the revised guidance, SilverBow's full year 2024 oil/liquids volumes are expected to comprise 48% of the Company's total production. Consistent with SilverBow's returns driven strategy, the Company's volume guidance assumes full ethane recovery in the NGL production stream for the remainder of 2024.

16:08 EDT Galecto enrolls first patient in GB1211 trial - Galecto announced that the first patient has been enrolled in an investigator-initiated Phase 2 trial to evaluate GB1211, Galecto's oral small molecule galectin-3 inhibitor candidate, at the Earle A. Chiles Research Institute, or EACRI, a division of Providence Cancer Institute in Portland, Oregon. The study aims to evaluate the safety and efficacy of GB1211 at a dose of 100mg twice daily in combination with pembrolizumab for the treatment of metastatic malignant melanoma and head and neck squamous cell carcinoma.

16:04 EDT Qualcomm up 5% after Q2 earnings beat - Qualcomm shares are up $8.71, or 5.31%, to $172.74 in after-hours trading.

13:26 EDT T-Mobile announces completion of acquisition of Ka'ena Corporation - T-Mobile US announced the completion of its acquisition of Ka'ena Corporation, which includes direct-to-consumer prepaid wireless brands Mint Mobile, internationally-focused value brand Ultra Mobile, and wholesale wireless solutions provider Plum. "And, as it does, the Un-carrier is letting Mint and Ultra customers know it's great to have them here by giving them magenta goodness right out of the gate - a few freebies and new offers just for being a part of Team T-Mobile... Ka'ena leadership, including Mint founders David Glickman and Rizwan Kassim, are joining T-Mobile alongside their teams and will continue to drive these brands. The brands will continue to operate autonomously but closely aligned to the broader T-Mobile brand and business, similar to T-Mobile's successful acquisition of MetroPCS in 2013. Ryan Reynolds will continue in his creative role on behalf of Mint. Their focus will be to deliver amazing products, value and digital-first experiences for more prepaid customers in more places... Now and over the next few months, T-Mobile is rolling out upgraded perks for current and future Mint and Ultra customers in the form of some of the Un-carrier's favorite benefits, and a few new ones," the company stated.

12:48 EDT Interactive Brokers reports April DARTs up 33% vs. last year - Interactive Brokers Group reported its Electronic Brokerage monthly performance metrics for April. Brokerage highlights for the month included: 2.339 million Daily Average Revenue Trades, 33% higher than prior year and 3% lower than prior month. Ending client equity of $457.8B, 34% higher than prior year and 2% lower than prior month. Ending client margin loan balances of $50.7B, 28% higher than prior year and 1% lower than prior month. Ending client credit balances of $105.8B, including $4B in insured bank deposit sweeps, 7% higher than prior year and 1% higher than prior month. 2.81 million client accounts, 26% higher than prior year and 2% higher than prior month. 188 annualized average cleared DARTs per client account. Average commission per cleared Commissionable Order of $3.00 including exchange, clearing and regulatory fees.

12:06 EDT Honda reports April U.S. sales up 0.4% to 116,586 units - American Honda April sales total 116,586 units, with balanced sales of cars and light trucks resulting in second best sales month of 2024. Honda brand sales topped 106,000 units in April, up 15.7% YoY with third straight month above 100,000 units. Honda electrified sales exceeded 21,000 units with CR-V hybrid and Accord hybrid achieving 46% and 51% model mix respectively.

12:01 EDT A10 Networks rises 20.5% - A10 Networks is up 20.5%, or $2.68 to $15.74.

12:00 EDT New York Community Bancorp rises 30.2% - New York Community Bancorp is up 30.2%, or 80c to $3.45.

12:00 EDT Ryerson falls -17.7% - Ryerson is down -17.7%, or -$5.04 to $23.51.

11:56 EDT Meta unveils 'Batman: Arkham Shadow' VR game for Meta Quest 3 - Meta (META) announced that Warner Bros. Interactive's (WBD) upcoming virtual reality game "Batman: Arkham Shadow" will be a Meta Quest 3 exclusive title, with the game set for release in late 2024. The company added that the official reveal of the game will occur at Summer Game Fest 2024 on June 7. Reference Link

11:11 EDT Uranium Energy 'applauds' U.S. Senate bill to ban Russian uranium imports - Uranium Energy "applauds" last night's vote by the United States Senate for passing H.R. 1042, a bill to ban Russian uranium imports into the United States, by unanimous consent. The House of Representatives passed the bill in December of 2023. Amir Adnani, Uranium Energy President and CEO stated: "We thank both chambers of Congress for passing this bipartisan bill that demonstrates the U.S. commitment to nuclear energy, the carbon free energy source that powers one in every five homes in America. Upon enactment, this will strengthen United States energy and national security, ending an untenable reliance on Russian uranium imports. This new law, in conjunction with the recently passed Nuclear Fuel Security Act, creates a firm foundation for long-term growth of the U.S. uranium industry to supply the fuel that powers American households, data centers, and industrial base with clean baseload power. As the fastest growing U.S. uranium company, we are delighted to have this exciting backdrop along with positive global uranium market fundamentals and advance the re-start of uranium production in Wyoming this August, followed by the resumption of our South Texas operations next year."

10:40 EDT S&P affirms ratings on Tesla, says EBITDA margin will remain strong - S&P Global Ratings affirmed all its ratings on Tesla, including its "BBB" issuer credit and issue-level ratings. "Despite price cuts to combat weakening affordability in a high interest rate environment, we expect Tesla's EBITDA margin to remain strong over the next two years," the agency said in a statement. S&P expects rising competition and further pricing pressure will lead to more volatility in Tesla's results in 2024 and 2025. It thinks Tesla will maintain an "adequate ratings cushion relative to investment-grade peers" in 2024 and 2025 amid downward pressure on its EBITDA margins and cash flows.

10:32 EDT Haoxi Health Technology Ltd trading resumes

10:24 EDT American Water board increases quarterly dividend 8.1% to 76.5c per share - American Water Works Company announced that its board of directors declared a quarterly cash dividend payment of 76.5c per share of common stock, an increase of 8.1%. "American Water continues to be an industry leader in dividend growth, which is a result of our successful execution of key strategic initiatives," said M. Susan Hardwick, President and CEO, American Water. "We recognize the value of our dividend and the role it plays in delivering exceptional shareholder value." The company expects to continue its dividend growth within a 7%-9% range over the long term, with a target dividend payout ratio of between 55%-60% of earnings. The increased quarterly dividend will be payable on June 3, 2024, to all shareholders of record as of May 14, 2024.

10:23 EDT Comerica Bank appoints Floyd Kessler as chief business risk, controls officer - Comerica Incorporated announced that Floyd Kessler has been named to the new role of Executive Vice President, Chief Business Risk and Controls Officer. Kessler will report to Peter Sefzik, Chief Banking Officer. Kessler will lead the Business Risk and Controls Office for Commercial Bank, Marketing, Customer Experience, the Retail Bank and Wealth Management, helping drive transformation of risk and control functions across all of Comerica's revenue divisions. Kessler has served in several risk management roles, most recently as Head of Non-Financial Risk Processes where he focused on the development of foundational risk management strategies during high growth periods

10:01 EDT O-I Glass falls -14.6% - O-I Glass is down -14.6%, or -$2.19 to $12.77.

10:01 EDT Leggett & Platt falls -36.9% - Leggett & Platt is down -36.9%, or -$6.66 to $11.41.

10:00 EDT A10 Networks rises 17.0% - A10 Networks is up 17.0%, or $2.23 to $15.29.

09:57 EDT Palisade Bio Inc trading resumes

09:48 EDT LendingClub rises 13.4% - LendingClub is up 13.4%, or $1.01 to $8.53.

09:48 EDT New York Community Bancorp rises 17.8% - New York Community Bancorp is up 17.8%, or 47c to $3.12.

09:47 EDT Bite Acquisition Corp trading resumes

09:47 EDT Leggett & Platt falls -30.5% - Leggett & Platt is down -30.5%, or -$5.52 to $12.55.

09:41 EDT CVRx Inc trading resumes

09:39 EDT Plutonian Acquisition Corp trading halted, volatility trading pause

09:37 EDT Bite Acquisition Corp trading halted, volatility trading pause

09:35 EDT Mobile-Health Network Solutions trading halted, volatility trading pause

09:35 EDT iLearningEngines Inc trading resumes

09:32 EDT GE HealthCare announces Revolution RT solution - GE HealthCare announced Revolution RT,i a new radiation therapy computed tomography solution with hardware and software solutions to help increase imaging accuracy, while simplifying simulation workflow for a more personalized and seamless oncology care pathway experience for clinicians and patients. The new Revolution RT is being unveiled at the European Society for Therapeutic Radiology and Oncology 2024 Congress in Glasgow, along with an updated and artificial intelligence-enhanced version of the Intelligent Radiation Therapy platform, which interfaces with the Spectronic magnetic resonance imaging Planner. Additionally, the company will showcase the newly acquired MIM Software portfolio, as well as other key innovations from GE HealthCare.

09:30 EDT Intchains Group Ltd (ADR) trading halted, volatility trading pause

09:29 EDT V2X awarded $75M in CBRN hazard detection work - V2X has been awarded a total of $75M in new and follow-on work to advance the next generation of threat detection and response to Chemical, Biological, Radiological, and Nuclear - CBRN - hazards. The first part of this funding, amounting to $50M, is a five-year project that will position V2X as the lead systems integrator under the CBRN Support to Command and Control program. In addition to the CSC2 contract, V2X is finalizing a $25M award to modernize and re-architect the CBRN threat warning and notification application, and predictive hazard propagation tools for enhanced operational decision support.

09:28 EDT Integral Ad Science announces integration with Roblox - Integral Ad Science (IAS) announced a first-to-market integration with Roblox (RBLX), a global immersive platform for connection and communication. Available for advertising campaigns on Roblox later this year, IAS's Viewability and Invalid Traffic Measurement products will provide advertisers increased transparency into the quality of their Immersive Ads within complex 3D environments. Roblox, which has more than 71.5M daily users as of Q4 2023, announced today its video ads are now available to all advertisers, enabling them to reach its community of users over the age of 132 at scale. With video ads, brands don't need to build custom 3D content and can use their existing video creatives for ad campaigns on Roblox. The new video ad format joins the broader suite of Roblox's Immersive Ads offerings that include other formats - for example, billboard-style image ads. Advertisers will be able to confidently reach their audience across immersive environments on Roblox with IAS's 3D in-experience Viewability and IVT Measurement with reporting available through the IAS Signal platform.

09:23 EDT Optex Systems announces $1.5M order for optical assemblies - Optex Systems has been awarded a new contract from a U.S. Government Prime Contractor, in support of a Night Vision Goggle system. The order value is $1.5M with deliveries covering most of fiscal 2025.

09:22 EDT Gaucho Group completes reverse stock split - Gaucho Group announced the completion of its reverse stock split, which took effect at 12:01 a.m. on May 1, 2024. This corporate action follows the detailed announcement made on April 29, 2024, and is part of a broader strategy to enhance stockholder value and ensure compliance with Nasdaq listing standards. Accompanying this corporate action, Scott Mathis, CEO and Founder of Gaucho Holdings, has addressed stockholders directly in a letter filed with the SEC as a Current Report on Form 8-K, detailing the rationale behind the reverse stock split. The letter outlines several key reasons for the reverse split, reaffirming the Company's commitment to strategic adjustments aimed at protecting and enhancing stockholder investments. Scott Mathis commented: "It is our mission to protect your investment and find ways to bring value back to our stockholders. This reverse split addresses several critical issues that have affected our stock, such as past dilutions linked to convertible notes and potential naked short selling. Key benefits of this strategic move include regaining compliance with Nasdaq listing requirements, making our stock marginable, and potentially attracting investment from major funds. Moreover, it aids in reducing our float, increasing the possibility of a short squeeze on positive developments, and improving our standing in financial indices such as the Russell 2000. Each of these steps is designed to enhance the stability and visibility of our shares in the capital markets."

09:18 EDT Cassava Sciences announces last day to trade SAVAW warrants on Nasdaq - Cassava Sciences has been advised by NASDAQ that end-of-day tomorrow May 2, 2024, will be the last and final trading day for SAVAW warrants on NASDAQ. After EOD May 2, the Company expects NASDAQ to no longer accept or execute any trade for SAVAW warrants. As a reminder, holders of SAVAW warrants are able to cash-exercise their warrants until 5pm New York time, Monday, May 6, 2024 for an exercise price of $33.00 per warrant. Holders who exercise SAVAW warrants will receive 1.5 shares of Cassava Sciences' common stock per warrant, for an effective price of approximately $22.00 per common share. There will be no opportunity to exercise SAVAW warrants after 5pm New York time, Monday, May 6, 2024. In addition, as an accommodation to SAVAW warrant holders, today the Company has instituted a process by which SAVAW warrant holders may cash-exercise their warrants using the Notice of Guaranteed Delivery for Exercise of Warrants/ The Company is offering holders of SAVAW warrants the opportunity to use the Notice if the procedures used by a financial institution for the exercise of SAVAW warrants cannot be completed by that financial institution on a timely basis before 5:00 p.m. New York City time on May 6, 2024. It is important to note that SAVAW warrant holders who wish to cash-exercise their warrants must submit the Notice and the payment of the exercise price before 5:00 p.m. New York City time on May 6, 2024. Please refer to the Notice itself for detailed information regarding its use.

09:16 EDT CytomX soars after saying CX-904 update coming next week - Shares of CytomX Therapeutics rallying after the company announced it will provide an initial CX-904 Phase 1a clinical data update on May 8 when reporting its Q1 results. The data update is being viewed by the market as sooner than expected. Shares of CytomX are up 98%, or $1.60, to $3.23 in premarket trading.

09:15 EDT PubMatic announces a partnership with Klarna - PubMatic announced a partnership with Klarna, the AI-powered global payments network and shopping assistant, to scale programmatic access to Klarna's native advertising inventory via PubMatic's Convert. The partnership will allow advertisers to reach and engage with Klarna's high-intent global audience of 150 million shoppers directly at the point of purchase. The integration with PubMatic provides Klarna with scaled access to demand via whichever demand-side platform a buyer is working with on both a self-serve and managed service basis.

09:14 EDT Micron first to ship critical memory for AI data centers - Micron Technology announced it is validating and shipping its high-capacity monolithic 32Gb DRAM die-based 128GB DDR5 RDIMM memory in speeds up to 5,600 MT/s on all leading server platforms. Powered by Micron's industry-leading 1beta technology, the 128GB DDR5 RDIMM memory delivers more than 45% improved bit density, up to 22% improved energy efficiency2 and up to 16% lower latency1 over competitive 3DS through-silicon via products. "With this latest volume shipment milestone, Micron continues to lead the market in providing high-capacity RDIMMs that have been qualified on all the major CPU platforms to our customers," said Praveen Vaidyanathan, vice president and general manager of Micron's Compute Products Group.

09:12 EDT Ondas' Airobotics secures service agreement for Optimus Systems - Ondas Holdings announced that its wholly-owned subsidiary Airobotics has signed an annual service agreement for the ongoing maintenance of the Optimus Systems purchased and operated by a local government entity in Dubai, United Arab Emirates. The new service agreement includes ongoing support services for the additional Optimus systems that were installed as part of the Optimus systems network across the city of Dubai. The deployed fleet of Optimus Systems has been extensively utilized by the local government entity, carrying out thousands of operational drone flights in densely populated areas. Airobotics believes that the Optimus Drone network in Dubai has the potential to grow to more than 20 systems over the next couple of years

09:11 EDT Catheter Precision appoints Marie-Claude Jacques as CCO - Catheter Precision (VTAK) welcomed Marie-Claude Jacques as Chief Commercial Officer. Marie-Claude will be responsible for the commercialization team including sales and marketing to develop new business opportunities and improve the customer experience. Before joining Catheter Precision Inc, Mrs. Jacques worked as Area Vice President, Commercialization & Strategy at Boston Scientific Corporation (BSX).

09:10 EDT Radware's Skyhawk Security unveils native CTEM solution - Skyhawk Security, a spinoff of Radware, unveils its cloud native Continuous Threat Exposure Management, CTEM, solution. The agentless approach empowers organizations to automate their CTEM program for the first time and operationalize it through Skyhawk's existing AI-based Synthesis Security Platform. "The increase in cloud breaches, despite all investments in CNAPP, proves that the cloud cannot be secured with traditional measures or static tools," said Chen Burshan, CEO of Skyhawk Security. "Our cloud native, agentless CTEM solution combines all the benefits of CTEM with cloud threat detection and response, providing organizations with the flexibility and agility they need to increase the maturity of their security strategy. Our solution is unique because we are continuously evaluating cloud environments from an adversarial point of view and based on the value of the data to the business, thus allowing teams to focus and prepare security responses for what really matters to their business and their board."

09:09 EDT CompuMed, FireStarter collaborate to enhance organ donation efforts - CompuMed announces a strategic collaboration with FireStarter. The teams aim to enhance organ donation efforts across the United States by pairing CompuMed's cutting-edge telediagnostic solutions with FireStarter's authentic and actionable marketing strategies. CompuMed and FireStarter will employ marketing strategies aimed at elevating CompuMed's comprehensive telediagnostic solutions for cardiology, radiology, pathology and pulmonology, as well as diagnostic equipment.

09:08 EDT Ageagle Aerial Systems announces its drones used by USACE - AgEagle Aerial Systems announces the U.S. Army Corps of Engineers, USACE, completed its training for National Guardsman utilizing, among other UAVs, the AgEagle eBee TAC drone, NDAA- compliant and the first fixed-wing drone to be added to the Defense Innovation Unit Blue UAS list and cleared to fly over humans. AgEagle CEO, Bill Irby, commented, "We believe that the use of our drones by the U.S. Army Corps of Engineers to certify their National Guardsman to use USA is a big win as it serves to validate our technology in the U.S. Military-Industrial complex. The UAS can be used to assist Enhanced Response Force Package soldiers in their vital yet dangerous missions. We look forward to continuing to provide mission-critical support to our growing commercial and government customer base as we further position ourselves as a leader in the increasingly growing UAS market."

09:06 EDT Oncternal Therapeutics reports inducement award under Nasdaq listing rule - Oncternal Therapeutics announced the approval of an inducement award to one new employee, Anne C. Hansen, who is joining Oncternal as Senior Director, Clinical Data Management. The award will be made on May 1, 2024 under Oncternal's 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Oncternal as an inducement to join the Company. The award will consist of an option to purchase 5,000 shares of Oncternal common stock. The option will have a 10-year term and an exercise price equal to the closing price of Oncternal's common stock on the date of grant. The option will vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the employee's start date, and the rest vesting in equal monthly installments over three years thereafter. The award was approved by Oncternal's compensation committee, comprised entirely of independent directors, as required by Nasdaq Rule 5635(c)(4), and will be granted as an inducement material to the employee entering into employment with Oncternal in accordance with Nasdaq Rule 5635(c)(4).

09:05 EDT WW for Business is partnering with Personify Health - WeightWatchers announced that WeightWatchers for Business is partnering with Personify Health to support employers looking to provide weight health care solutions for their populations. Now, organizations using the Personify Health personalized health platform will have integrated access to WeightWatchers for Business and its full-spectrum weight health platform, which is customizable to support benefit coverage decisions. "Obesity is a serious and costly, yet common issue. Employers are well-positioned to play an important role in helping their employees manage their weight and improve their overall health, but they can't go it alone," said Jeffrey Jacques, MD, chief medical officer at Personify Health. "WeightWatchers has evolved with the latest research and science, and we recognize their recent innovations to provide scalable and flexible health solutions that address key aspects of weight health. We're proud to add WeightWatchers for Business to our partner ecosystem, providing an array of tools to help members achieve their desired personalized weight health and cardiometabolic goals."

09:04 EDT 180 Degree Capital notes average discount of NAV per share to stock price - 180 Degree Capital noted that the average discount between its estimated daily net asset value per share and its daily closing stock price during April 2024 and year-to-date through the end of April 2024, were approximately 14% and 20%, respectively.1 This discount was approximately 16% on April 30, 2024. As previously disclosed in a press release on November 13, 2023, 180 Degree Capital's Board of Directors has set two measurement periods of January 1, 2024 to December 31, 2024, and January 1, 2025 to June 30, 2025, in which it will evaluate the average discount between TURN's estimated daily NAV and its closing stock price pursuant to a Discount Management Program. Should TURN's common stock trade at an average daily discount to NAV of more than 12% during either of these measurement periods, 180 Degree Capital's Board will consider all available options at the end of each measurement period including, but not limited to, a significant expansion of 180 Degree Capital's current stock buyback program of up to $5 million, cash distributions reflecting a return of capital to shareholders, or a tender offer.

09:02 EDT LPL Financial: Journey Financial joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisors Timothy J. Heisterkamp and Max Neese have joined LPL Financial's broker-dealer, RIA and custodial platforms. They reported serving approximately $200 million in advisory, brokerage and retirement plan assets and join LPL from Cambridge. Heisterkamp, an advisor since 1998, built the Jefferson, Iowa-based practice from the ground up after an initial career as a high school economics teacher. Neese's entry into the financial services sector was inspired early on by Heisterkamp, who was a guest speaker at Neese's high school class to discuss the world of investing.

08:57 EDT Monogram Orthopaedics provides regulatory update following FDA meeting - Monogram Orthopaedics provided an update related to the regulatory and commercialization path for its mBos surgical system following its meeting with the U.S. Food and Drug Administration. On April 19, 2024, Monogram received written feedback from the FDA regarding the Company's Q1 2023 pre-submission request. Subsequently, Monogram conducted a teleconference meeting with the FDA on April 24, 2024, to discuss the written feedback further and obtain feedback on the Monogram mBos TKA System verification test plan, including a proposed clinical trial protocol on an outside the U.S. target population. Management believes the feedback was comprehensive and will be advantageous for preparing a successful 510(k) submission to obtain clearance. The Company shared with the FDA various test protocols essential for establishing the safety and effectiveness of the Monogram mBos TKA System and a synopsis of its proposed OUS clinical investigation plan. Based on the feedback, management assesses that: the proposed testing plan generally appears acceptable to address the technical differences identified with the proposed predicate device, and for the active embodiment of its product, a clinical testing plan that includes approximately 100 knee surgeries conducted on an OUS population at three sites with three months of follow-up should generally be sufficient for evaluating the safety and effectiveness of the Monogram mBos TKA System. Notably, on March 21st, the Company announced that it had modified the Monogram mBos TKA System to reduce the likelihood of an FDA clinical data request with its submission. In their written response the FDA indicated they support a least burdensome approach to acquiring clinical data. Management anticipates running an OUS clinical trial could save the Company significant cost and time. Currently, management estimates the cost to run an OUS clinical trial as proposed to be approximately $1.5M. The Company plans to run a clinical trial to support post-launch marketing irrespective of whether it will be needed for obtaining regulatory clearance with the FDA. Given the favorable FDA feedback for using OUS clinical data, Monogram management anticipates establishing an ongoing OUS clinical strategy to support its innovation strategy. Access to an extensive OUS surgeon and hospital network and an accommodative FDA posture towards OUS data could accelerate the development and commercialization of its technology pipeline, including mVision, its novel tracking solution that aims to eliminate point based registration and tracking with large fiducial based arrays. The Company recently announced that the Verification and Validation testing will be largely complete in Q2 of 2024 and anticipates a 510(k) submission to follow in the second half of 2024. The Company's plan to aggressively accelerate 510(k) submission for its mBos surgical system with design modifications that management believes reduce the risk of a clinical trial request is on track. The Verification and Validation testing is underway, and the Company has largely completed various mandated packaging, biocompatibility, sterilization, and cleaning validations. Except for ongoing IEC testing, most tests that rely on outside vendors are on track or largely complete. For IEC testing, the Company has largely completed various mandated radiated emissions and immunity testing. The paperwork reviews are largely complete, and various electromechanical and safety tests are starting soon. The Company believes the system will perform favorably in outstanding IEC testing based on completed internal testing and various design considerations. One of the most demanding test protocols is the Human Factors Evaluation and Design Validation, which requires at least 15 surgeons to use the system in a simulated surgery. The Company is using much of the data from these labs to test other aspects of the system, such as system accuracy. The Company has completed six simulated surgeries, with a significant remaining portion planned in May 2024. Monogram has engaged MCRA to support its regulatory strategy for submission.

08:55 EDT Paychex increases quarterly dividend 10% to 98c per share - Paychex announced that its board of directors approved a quarterly dividend of 98c per share, an increase of 9c from the prior quarterly dividend of 89c per share, payable on May 30 to shareholders of record as of May 10.

08:55 EDT NioCorp to voluntary delist from TSX - NioCorp Developments announces that, further to its press release dated April 17, 2024, the board of directors has approved the voluntary delisting of NioCorp's common shares from the Toronto Stock Exchange, It is expected that NioCorp's common shares will be delisted from the TSX effective as of close of markets on May 3, 2024. NioCorp's common shares will continue to be listed and trade on the Nasdaq Capital Market under the symbol "NB".

08:50 EDT Altamira Therapeutics files provisional patent application for OligoPhore - Altamira Therapeutics has filed a provisional patent application with the United States Patent Office which covers nanoparticles comprising the Company's OligoPhore platform and siRNA targeting the p65 protein, a component of the NF-B transcription factor. The provisional patent application describes novel nanoparticle compositions based on OligoPhore, Altamira's peptide-based oligonucleotide delivery platform, or derivatives thereof in combination with siRNA sequences designed to silence p65. Activation of p65 has been observed in multiple types of cancer as well as in many inflammatory diseases and its function has been implicated in the pathogenesis of these diseases. For instance, p65 is a well-known key checkpoint in rheumatoid arthritis inflammation, and thought to regulate cell proliferation, cell death, and stimulate metastasis in cancer. The new filing is intended to extend Altamira's intellectual property related to its AM-411 development program for RA treatment, among others.

08:46 EDT Microchip introduces RT PolarFire SoC FPGA - Developers of spacecraft electronics utilize radiation-tolerant field programmable gate arrays to ensure high performance, reliability, power-efficiency and the best-in-class security for emerging space domain threats. To take it a step further and help provide fast, cost-effective software customization, Microchip Technology has introduced the RT PolarFire system-on-chip FPGA. Developed on Microchip's RT PolarFire FPGA, it is the first real-time Linux capable, RISC-V-based microprocessor subsystem on a flight-proven RT PolarFire FPGA fabric. With today's announcement, developers can now start designing using the commercially available PolarFire SoC device and Libero SoC development tools. Along with Microchip's extensive Mi-V ecosystem, PolarFire SoC solution stacks, the PolarFire SoC Icicle Kit or the PolarFire SoC Smart Embedded Vision Kit, developing lower power solutions for the challenging thermal environments seen in space can happen today.

08:44 EDT Peak Bio, Akari Therapeutics announce portfolio prioritization plan - Akari Therapeutics (AKTX) and Peak Bio (PKBO) announced completion of a joint portfolio prioritization review pursuant to which the combined entity, following completion of the previously announced merger of Akari and Peak, will focus on Peak's ADC platform technology and Akari's PAS-nomacopan Geographic Atrophy program. Peak's ADC platform technology is a proprietary technology using antibody plus linker plus Peak Bio toxin with immune modulation and includes a novel pre-clinical ADC candidate targeting TROP-2. Akari's PAS-nomacopan is a bispecific complement and leukotriene B4 inhibitor with prolonged duration of action being developed for GA. Key Elements of Program Prioritization: ADC toolkit: Oncology platform includes a novel pre-clinical ADC candidate targeting TROP-2; Strategy includes continued IND enabling development; Strategy includes developing and progressing our novel toxin including our lead toxin, PH-1 which can be used in multiple important cancer targets including our TROP-2 candidate; Ongoing and continued business development activities with significant market interest in ADC candidates. PAS-nomacopan for Geographic Atrophy: Complement only inhibitors recently approved for treatment of GA; PAS-nomacopan has been shown in animal models to have prolonged biologic residence in the eye, suggesting ability for q2 to q4 month dosing, a potentially important competitive advantage; PAS-nomacopan, with its unique, non-pegylated bispecific inhibition of leukotriene B4 and complement may offer safety and/or efficacy advantages over traditional complement inhibitors; Continued IND enabling development including full scale manufacturing of drug for clinical use with a pre-IND meeting expected 1H 2024. Programs for Further Evaluation: HSCT-TMA: Akari's HSCT-TMA program will be suspended, with enrollment in its currently active pediatric clinical study discontinued due to cost and timeline; The post-closing combined company will work closely with FDA to define the best path forward for this technology; Based upon cost and timeline will consider the opportunity for partnership and licensing, specifically as it relates to the Priority Review Voucher. PHP 303: Peak Bio's Phase II ready PHP 303 program for Alpha 1 anti trypsin deficiency, a rare orphan condition, will be discontinued; The post-closing combined company will continue ongoing business development discussions around this technology. Nomacopan: Continue to seek partnership opportunities for licensing, proof of concept studies, and clinical trials

08:43 EDT Marriott sees RevPAR higher in international markets vs. U.S. and Canada

08:41 EDT Alternus Clean Energy set to acquire over 80MWp of operating solar PV - Alternus Clean Energy announced the signing of definitive agreements with a U.S. based fund to acquire over 80 MWp of operating portfolio spanning across the U.S. The Portfolio consists of 33 projects, distributed across eight states, showcasing a geographical diversification within the U.S. The portfolio has significant long-term agreements with 16 different counterparties. Notably, approximately 20% of these fall within the AAA and AA rating categories, such as Duke Energy, enhancing the financial stability and predictability of revenue streams. The Portfolio is expected to generate an average of $6.7 million of revenue and $5.1 million of operating income annually and represents an outstanding opportunity to acquire established assets generating reliable cash flows backed by long-duration contracts. The total consideration is approximately $60 million including existing project debt. Alternus plans to fund the acquisition at the project level with the target for completion by the end of Q2 2024.

08:39 EDT Sellas Life Sciences announces preliminary data from Phase 2a t rial of SLS009 - SELLAS Life Sciences Group announces the preliminary data from Phase 2a trial of SLS009, a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia and successful filing of a provisional patent application around the ASXL1 mutation and SLS009, including all CDK9 inhibitor drugs. ASXL1 mutations are associated with poor prognosis in all myeloid diseases, owing to the reduced response to the current treatment options. Study highlights: As of April 19, 2024 data cutoff, a 57% overall response rate has been achieved thus far, in the selected optimal dose regimen of 30 mg BIW, far surpassing the targeted 20% rate. 4/4 r/r AML patients with ASXL1 truncating mutations at the selected dose level achieved an overall response and are alive. 5/8 of r/r AML patients, across all dose levels, with ASXL1 truncating mutations treated with SLS009 achieved an overall response. A review of the mutational status of the patient in the Phase 1 trial with SLS009 monotherapy, who achieved a CR lasting 8+ months, revealed that the patient also harbored an ASXL1 mutation. The ASXL1 mutation is found in both hematological malignancies as well as solid tumors. All patients in the study are diagnosed with AML refractory to or relapsed after venetoclax-containing regimens. Enrollment and treatment will be focused on the participants in the expansion cohort receiving 30 mg BIW dose and diagnosed with the ASXL1 mutation.

08:38 EDT Motorsport Games announces the sale of Traxion - Motorsport Games is announcing the sale of its gaming media outlet Traxion to Traxion.GG Ltd, a UK subsidiary of Grid Finder Ltd for $250,000. This strategic decision continues Motorsport Games' ongoing efforts to streamline operations, reduce operational costs and sell off components not considered core to the future of the business. The sale is expected to allow Motorsport Games to focus more intensely on development of high-quality racing games with $200,000 of the deal in cash and $50,000 in future marketing efforts through the outlet. Motorsport Games retains the option to access the video platforms for future broadcasts of the Le Mans Virtual Series and 24 Hours of Le Mans Virtual. "This transaction is another component piece in our strategy to leverage elements of market value, bringing cash into the business whilst doubling-down on our primary focus - high-quality gaming products," commented Stephen Hood, CEO and President of Motorsport Games. "Traxion stood for quality racing game journalism, helped grow the racing video games and simulation market - and we are excited to see the brand revived under new ownership."

08:37 EDT Supernus partners with Busy Philipps to shine spotlight on ADHD in women - Actress, author, podcaster, and mother of two, Busy Philipps is teaming up with Supernus Pharmaceuticals to share her personal journey with attention-deficit/hyperactivity disorder - one of the most common psychiatric diagnoses in adults - as well as her experience with Qelbree, a non-stimulant medication for the treatment of ADHD. Busy has been vocal about her personal experience living with ADHD for years, but now she is revealing what it means to be a woman navigating ADHD and wants other women who may be struggling to know they are not alone. Boys are two times more likely than girls to be diagnosed. While boys' symptoms often fit the stereotypical ideas of hyperactive ADHD, girls' inattentive symptoms are often overlooked. As a result, ADHD often goes undiagnosed in young girls, leading to more adult females being undiagnosed and therefore untreated - a sentiment reflective of Busy's own experience.

08:36 EDT Aileron Therapeutics announces data from Cohort 1 of Phase 1b trial of LTI-03 - Aileron Therapeutics announced positive data from Cohort 1 of the ongoing Phase 1b clinical trial evaluating the safety and tolerability of inhaled LTI-03 in patients diagnosed with idiopathic pulmonary fibrosis. Following inhaled administration of low dose LTI-03, a positive trend was observed in seven out of eight biomarkers with evidence of reduced expression among profibrotic proteins produced by basal-like cells and fibroblasts that contribute to the progression of IPF, including data from several biomarkers that were statistically significant, reinforcing the potential of LTI-03 to improve lung function and reverse the course of IPF. "We find it encouraging that low dose LTI-03 achieved statistical significance in three out of eight biomarkers evaluated in the trial" said Brian Windsor, Ph.D., President and Chief Executive Officer of Aileron. "This, paired with the positive trends observed in several of the other biomarkers, strengthens our belief that LTI-03 has the potential for disease stabilization or even reversal. We look forward to continuing to evaluate LTI-03 in the ongoing Phase 1b study and sharing results from the high-dose cohort later this year."

08:36 EDT Marriott sees returning $4.2B-$4.4B to shareholders in 2024

08:35 EDT Real Brands signs LOI to acquire Vapor Shark assets - Real Brands has signed a letter of intent to acquire substantially all the Vapor Shark assets. Since 2010, Vapor Shark has been a pioneer in the online B2B and B2C business, developing robust and untapped sales channels and e-commerce back-end pick and ship capabilities able to manage regulated product distribution. It also maintains recognizable service brand reputation in the vapor markets. Highlights of Vapor Shark capabilities have been: capable of large volume distribution. 9+ years of combined experience in consumer-packaged goods and compliance. A full complement of certifications and registrations. The highest quality and efficacious ingredients with full transparency.

08:34 EDT IBN announces 'From Lab to Launch' podcast featuring Clene CEO - IBN announces that Rob Etherington, President, Director and CEO of late clinical-stage biopharmaceutical company Clene, recently appeared on From Lab to Launch, a podcast sharing the inspiring stories of founders, investors, scientists, engineers and pioneers in the life sciences sector. The podcast, hosted by Meg Sinclair, is available for on-demand listening on From Lab to Launch. During the interview, Etherington discussed Clene's work to address the critical unmet medical need relating to neurodegenerative diseases

08:32 EDT First Solar: MN8 Energy sources 457 MW of american solar modules - First Solar announced that MN8 Energy has placed orders for 457 megawatts of advanced thin film solar modules, including 170 MW of Series 6 Plus bifacial modules and 287 MW of Series 7 modules. The modules will power projects in the northeastern and southern United States.MN8, founded as Goldman Sachs Renewable Power in 2017, owns and operates a 3.2 gigawatt GW portfolio, delivering renewable energy solutions to over 40 corporates, 70 government entities, and 20 utilities. MN8 previously transacted with First Solar in their acquisition of the 123 MW American Kings Solar project in California. "We are pleased to continue our relationship with First Solar, building certainty and resilience into our development pipeline," said David Fernandez, chief operations officer, MN8. "By executing these agreements, MN8 demonstrates strong support for developing a robust domestic supply chain for the US renewable industry that upholds the highest environmental, sourcing, and manufacturing standards. Furthermore, we're thrilled to be collaborating with a partner that shares our commitment to responsibly and domestically produced solar, strengthening our industry's social license to operate."

08:32 EDT Capital Power discontinuing pursuit of Genesee CCS project - Capital Power is discontinuing pursuit of the Genesee CCS project. Through our development of the project, we have confirmed that CCS is a technically viable technology and potential pathway to decarbonization for thermal generation facilities including Genesee. However, at this time, the project is not economically feasible and as a result we will be turning our time, attention, and resources to other opportunities to serve our customers with balanced energy solutions. Capital Power looks forward to exploring CCS at Genesee and certain assets in our North American fleet in the future as economics improve.

08:27 EDT FOREWARN partners with Greater Metropolitan Association of REALTORS - FOREWARN announced that Greater Metropolitan Association of REALTORS will offer FOREWARN services to its 7,500+ members it serves throughout Macomb, Oakland, and Wayne County in metro-Detroit to promote proactive real estate agent safety.

08:26 EDT CVS Health seeing medical cost pressures in Medicaid business - Says visibility on Q1 medical claims impaired by cyber attack on Change Healthcare. Expects to add 50-60 Oak Street centers in 2024. Sees no additional share repurchases in 2024.

08:23 EDT Akari Therapeutics, Peak Bio announce portfolio prioritization plan - Akari Therapeutics (AKTX) and Peak Bio Inc. (PKBO) announced completion of a joint portfolio prioritization review pursuant to which the combined entity, following completion of the previously announced merger of Akari and Peak, will focus on Peak's ADC platform technology and Akari's PAS-nomacopan Geographic Atrophy program. Peak's ADC platform technology is a proprietary technology using antibody plus linker plus Peak Bio toxin with immune modulation and includes a novel pre-clinical ADC candidate targeting TROP-2. Akari's PAS-nomacopan is a bispecific complement and leukotriene B4 inhibitor with prolonged duration of action being developed for GA. "As part of the merger process, the boards of each company collaboratively decided on this portfolio prioritization plan. The boards believe by prioritizing the ADC and PAS-nomacopan GA programs the post-closing combined company will be in the best position to secure business development opportunities and funding while continuing to advance these important programs," said Hoyoung Huh, M.D., Ph.D. Chairman, Peak Bio, and Ray Prudo, M.D. Chairman, Akari Therapeutics.

08:20 EDT LiveRamp announces partnership with Environics Analytics - Environics Analytics announces a partnership with LiveRamp. Under the terms of this partnership, EA will be the sole provider of LiveRamp's suite of products and services in Canada. The addition of LiveRamp's platform to EA's existing data, analytics and clean room capabilities enable businesses to successfully navigate today's challenging marketing environment. The combined solution extends the value of organizations' first-party data, improving connectivity across the media ecosystem and, most importantly, ensuring accurate measurement of the impact of advertising spend without relying on third-party cookies. EA will manage all products and services within its comprehensive ISO 31700-1 Certified data and governance framework.

08:19 EDT Kraft Heinz, TGI Fridays extend frozen appetizers deal - Kraft Heinz and TGI Fridays announced an exclusive, perpetual extension of their existing licensing deal where Kraft Heinz makes restaurant-inspired, TGI Fridays branded frozen appetizers for retail across North America. Kraft Heinz and TGI Fridays have had a successful licensing partnership since 2001. With the new perpetual licensing deal, which supersedes the most recent licensing deal signed in 2015, Kraft Heinz will continue to develop and sell delicious TGI Fridays frozen appetizers and snacks.

08:18 EDT Editas Medicine, Bristol Myers extend alpha-beta T cell collaboration - Editas Medicine (EDIT) announced a two-year extension to the collaboration with Bristol Myers Squibb (BMY) under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The extension also has options to extend the collaboration for up to an additional two years. Under the collaboration, Bristol Myers Squibb has opted into 13 different programs across 11 gene targets to date. Two programs are currently in IND-enabling studies, and four programs are in late-stage discovery. Under the terms of the original agreement, Editas Medicine may develop genome editing tools and Bristol Myers Squibb will have rights to opt-in to such genome editing tools for development of gene edited alpha-beta T cell therapies. For each new experimental medicine that Bristol Myers Squibb develops and commercializes using opted-into genome editing tools, Bristol Myers Squibb will pay Editas Medicine potential future milestone payments. Following the approval of any products resulting from the collaboration, Editas Medicine is also eligible to receive tiered royalties on net sales. Editas Medicine and Juno Therapeutics, originally entered into a strategic research collaboration in 2015 focused on creating chimeric antigen receptor T and high-affinity T cell receptor cell therapies to treat cancer. The exclusive research period under the original collaboration was set to expire in 2020 and was amended in 2019 with Celgene/Bristol Myers Squibb replacing the original agreement and allowing Editas to develop non-alpha-beta T cell therapies, while expanding Celgene/Bristol Myers Squibb's access to gene-edited alpha-beta T cells beyond oncology. The current research agreement was set to expire in 2024 and has now been extended to 2026 with two options for one-year extensions extending the relationship into 2028.

08:17 EDT UiPath names Raghu Malpani CTO - UiPath (PATH) announced Raghu Malpani is joining the company as CTO. Malpani will report to chief innovation officer and UiPath executive chairman Daniel Dines and will lead the company's engineering teams. Malpani most recently served at Microsoft (MSFT) as corporate VP for the Microsoft 365 Application and Data Platform.

08:16 EDT Lipocine completes dosing in study of postpartum depression candidate LPCN 1154 - Lipocine announced that dosing of subjects has been completed in the pivotal pharmacokinetic study designed to support a New Drug Application for LPCN 1154, being developed as a treatment of postpartum depression. Lipocine anticipates topline results late in Q2, with the goal of NDA submission by the end of Q4. Lipocine has confirmed with the FDA acceptance of a proposal for a 505(b) NDA filing enabled by a single pivotal PK study comparing exposure of LPCN 1154 with the approved IV infusion of brexanolone.

08:14 EDT Primech Holdings engages Strategic Investor Relations - Primech Holdings has engaged Strategic Investor Relations, a premier investor relations firm, to enhance Primech's visibility in the financial community and support its ongoing efforts to engage and educate current and potential investors about the company's growth and strategic initiatives. With this new partnership, Primech aims to refine its communication strategies and investor relations activities to ensure stakeholders are fully informed and engaged with the company's progress and prospects. "Engaging with Strategic Investor Relations represents an important step towards strengthening our relations with current and prospective investors and better communicating our financial story and market opportunities," said Kin Wai Ho, Chief Executive Officer of Primech. "We are committed to enhancing our transparency and engagement with the investor community as we expand and innovate within the facilities services sector. Together with the expertise of Strategic Investor Relations, we are confident in our ability to communicate our vision and operational successes more effectively, driving enhanced shareholder value."

08:14 EDT Leidos awarded $206M NGA mission software modernization contract - Leidos was recently awarded a contract by the National Geospatial-Intelligence Agency's Exploitation Services Program to sustain and modernize geospatial processing for increased efficiency and interoperability. The single award, indefinite delivery, indefinite quantity contract, referred to as Maru, has a ceiling value of $206M if all task orders are exercised over a five-year period of performance. Under Maru, Leidos will provide mission software development, sustainment and technology insertion, testing and user-acceptance, and enterprise deployment of analytical capabilities for geospatial processing.

08:12 EDT Tevogen provides year end update, upcoming objectives - Tevogen Bio is in discussions to acquire cell therapy manufacturing facilities that are expected to provide Tevogen Bio with the capability for both clinical and commercial manufacturing of drug candidates from its ExacTcell technology platform. These facilities would support manufacturing for TVGN 489's continued development, as well as provide the potential for future clinical trials for virally induced cancers and multiple sclerosis. Tevogen Bio is evaluating several funding options to support its ambitious growth plans over the next 12 months to initiate in-house manufacturing, clinical trials, and other operational expenses. "Saving lives remains our duty, and to that end, we remain committed to furthering our ExacTcell(TM) technology platform by moving Tevogen's allogeneic cytotoxic CD8+ T lymphocytes (CTLs) into the next phase of clinical trials" said Dr. Ryan Saadi, Founder and Chief Executive Officer of Tevogen Bio. "Moving the first clinical product of Tevogen's ExacTcell platform, an allogeneic target specific CTL, from inception to clinical trial in just 18 months validates Tevogen's unique business model. I would also like to assure numerous Long COVID patients and their families who have contacted us that exploring the therapeutic potential of TVGN 489 for Long COVID remains my personal priority."

08:10 EDT Aeterna Zentaris announces effective date of share consolidation - Aeterna Zentaris has filed articles of amendment to effect the previously announced share consolidation of its issued and outstanding common shares on the basis of one post-Consolidation Common Share for every four pre-Consolidation Common Shares. The Consolidation was approved by shareholders of Aeterna at the Company's special meeting of shareholders held on March 12, 2024 along with other matters related to the merger of equals transaction with Ceapro pursuant to a plan of arrangement. The Consolidation will reduce the number of Common Shares issued and outstanding from approximately 4,855,876 Common Shares to approximately 1,213,969 Common Shares, subject to the elimination of fractional Common Shares. The Common Shares are expected to commence trading on the Toronto Stock Exchange and on the Nasdaq Capital Market on a post-Consolidation basis on or about the opening of trading on May 3, 2024.

08:05 EDT Wingstop sees 2024 domestic SSS up in low double digits

07:51 EDT Vision Marine files patent for electric marine vessel cooling system control - Vision Marine Technologies announces the filing of a patent application for its innovative method and apparatus for controlling the cooling water system of an electric marine vessel. The patent application addresses the unique challenges of designing and operating electric propulsion systems in marine environments. As advances in battery technology continue to enable the transition to full-electric watercraft, Vision Marine strives to develop innovative solutions to ensure optimal performance, efficiency, and safety of electric marine vessels' propulsion systems in all conditions.

07:47 EDT Jacobs to deliver final design on Brightline West high speed rail Nevada segment - Jacobs was selected by Brightline West high-speed rail system for final design of the Nevada rail segment. Brightline West is a 218-mile, $12B passenger rail project connecting Las Vegas to Southern California twice as fast as the average drive time. The Nevada Segment of the system, delivered in strategic partnership with Brightline West and the Nevada Department of Transportation, will be a 34-mile segment of high-speed rail alignment from the south end of the Las Vegas Strip to the Nevada/California border. Jacobs will provide final design of the trackwork and 22 complex structures, including grading, drainage, geotechnical investigations, traffic engineering and utility coordination. When complete, Brightline West's fully electric, zero emission system will take passengers from Las Vegas to Los Angeles in 2 hours and 10 minutes and is estimated to remove more than 400,000 tons of CO2 emissions per year.

07:44 EDT Marriott sees Q2 worldwide comparable systemwide RevPAR growth 4%-5%

07:42 EDT Stack Capital invests $8M into Canva - Stack Capital Group has invested $8M into Canva, a global online visual communication and collaboration business that empowers its users, from novices all the way up to industry professionals, to design anything and publish anywhere, using its dynamic all-in-one platform.

07:38 EDT Merck: KEYNOTE-811 trial meets dual primary endpoint of OS - Merck announced that the Phase 3 KEYNOTE-811 trial evaluating KEYTRUDA or pembrolizumab, Merck's anti-PD-1 therapy, in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy met its dual primary endpoint of overall survival OS for the first-line treatment of patients with human epidermal growth factor receptor 2 or HER2 -positive locally advanced unresectable or metastatic gastric or gastroesophageal junction, GEJ, adenocarcinoma. Based on results from KEYNOTE-811, KEYTRUDA is approved in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma whose tumors express PD-L1 as determined by an FDA-approved test. This indication is approved by the U.S. Food and Drug Administration FDA under accelerated approval regulations based on the objective response rate ORR and durability of response demonstrated at an earlier analysis. Continued approval of this indication may be contingent upon verification and description of clinical benefit at the final analysis of the KEYNOTE-811 study. In the final analysis of this trial, KEYTRUDA in combination with trastuzumab and chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS compared to placebo in combination with trastuzumab and chemotherapy in the intention-to-treat ITT study population, with the greatest benefit observed in patients whose tumors expressed PD-L1. The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies; no new safety signals were identified. Results will be presented at an upcoming medical meeting and shared with regulatory authorities worldwide.

07:38 EDT Bombardier CEO says 'well on track ' to meet 2025 objectives - Bombardier will host its Investor Day on May 1st, 2024, at its new state-of-the-art Aircraft Assembly Centre at Pearson Airport in Toronto. During the event - which will be webcast live - Bombardier's executive leadership will review the company's strong performance over the past three years and provide an in-depth look at how the company is set to meet its 2025 commitments. Eric Martel, President and Chief Executive Officer, and Bart Demosky, Executive Vice President and Chief Financial Officer, will be joined by members of Bombardier's executive leadership team in Toronto to outline the company's progress on several fronts, including the expansion of Bombardier Defense, growth in Services and in its pre-owned participation, as well as the company's dedication to sustainability and operational excellence. They will also provide an update on how the company has positioned itself for growth through 2030 by building a resilient business, based on predictable and diversified revenue streams and supported by continued strategic investments. "Since starting our turnaround plan in 2020, our teams have delivered textbook-worthy results on all fronts, consistently meeting or surpassing many of our objectives. Bombardier is well on track to meet its 2025 objectives thanks to everyone's collective focus on executing our plan flexibly, creatively and passionately," said Martel. "As we now look toward the second half of what has already been a historic decade for the company, we are focused on creating even more value for shareholders by building on a predictable and resilient foundation. Bombardier will have room to grow organically, as well as to deploy capital strategically." Since the end of 2020, through to the end of 2023, Bombardier has recorded a 13% CAGR on revenues, which includes an impressive 21% CAGR for Services. Adjusted EBITDA grew at a rate of 84% over this time frame with adjusted EBIDTA margin growing by a factor of greater than 4 times to more than 15% in 2023. This well-rounded performance has put Bombardier on a clear path to achieve its stated 2025 objectives of more than $9B in revenues and more than $1.625B in adjusted EBITDA, with more than $900M in free cash flow and a net leverage ratio of 2.0x to 2.5x.

07:27 EDT Staar Surgical names Nancy Sabin CMO, Sisitsky as general counsel - STAAR Surgical Company announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel. Both will serve on the Company's executive committee and report to Tom Frinzi, STAAR Surgical's President and CEO

07:26 EDT MingZhu Logistics to acquire Mingfu Liquor, no terms disclosed - MingZhu Logistics announced it has entered into a non-binding memorandum of understanding to acquire Xiamen Mingfu Liquor Industry Co., Ltd., a China-based distributor of Baijiu. The acquisition, subject to a final agreement, will help accelerate growth of MingZhu's premium liquor business in China, which includes self-owned Baijiu brands and commercial distribution for third party brands. Mingfu Liquor is a liquor distributor that focuses on distributing Baijiu brewed in Maotai town, Guizhou. Baijiu is considered to be China's national drink and is the dominant spirits sold in the domestic China market, with the "white liquor" a normal staple at occasions from family gatherings to business banquets while the Maotai town is the most well-known origin of Baijiu.

07:25 EDT ProPetro Holding sees Q2 as a 'slow-to-no-growth environment' - The Company now expects to be on the low end of our prior guidance range for full-year 2024 incurred capital expenditures of $200 million to $250 million. Frac fleet effective utilization is expected to be between 14 to 15 fleets during the second quarter 2024. Outlook Mr. Sledge added, "Looking ahead, we expect demand for our differentiated service quality and next generation equipment to remain strong. We believe the recent transition and investment in our fleet will contribute to industry-leading efficiencies and high customer satisfaction, as evidenced by our recently announced multi-year agreement to advance our partnership with ExxonMobil. Additionally, with our strong balance sheet and steady free cash flow generation, we continue to make excellent progress on our strategic priorities, and we will continue to evaluate opportunities to further enhance financial returns." Sledge concluded, "We are entering the second quarter with exciting momentum with our industrialization strategy, which is designed for the future of our sector and industry. In light of the market pressures that we and our peers face in a slow-to-no-growth environment, continued focus on our execution is paramount. With our strategic initiatives largely in place, we believe ProPetro is well-positioned to provide the reliable completion services, next-generation technologies and competitive costs that customers seek in the consolidating E&P space. As we further industrialize our business, optimize operations, modernize our fleet and remain opportunistic in value-accretive transactions and capital returns, aligned with our disciplined capital allocation framework, we are confident in ProPetro's ability to deliver increased shareholder value."

07:22 EDT Bombardier announces NetJets revealed as previously confidential buyer - Bombardier announced that its long-valued client NetJets has been revealed as the previously confidential buyer of 12 Challenger 3500 aircraft. The firm transaction initially announced in December 2023 was valued at US$326.4 million based on list prices at the time of signing, but the landmark deal could be more than US$6 billion if all optional 232 Challenger 3500 jets are exercised over time. "The Challenger 3500 jet continues to impress with its ultimate combination of refined cabin experience, proven reliability and top performance, perfectly aligning with the needs of NetJets' discerning client base," said Eric Martel, President and CEO, Bombardier. "We couldn't be prouder to see the Challenger 3500 business jet join the NetJets' fleet as we write the next chapter of our long-term collaboration."

07:20 EDT BioCardia announces primary endpoint results of CardiAMP trial - BioCardia announced the primary endpoint results of the open label roll-in cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial. Results from the open label roll-in cohort of patients having chronic myocardial ischemia with refractory angina showed an average increase in exercise tolerance of 107 seconds and an average of 82% reduction in angina episodes at the primary six-month follow-up endpoint compared to before receiving the study treatment. All of the patients responded positively to therapy, as measured by increased exercise tolerance and greatly reduced angina. "The clinical research results presented for the roll-in cohort from our CardiAMP CMI Trial highlight BioCardia's continuing efforts to transform the treatment paradigm in refractory angina through the promise of a one-time cost effective minimally invasive autologous cell-based therapy," said Peter Altman, President and CEO. "These results strongly support our continued development of this novel therapeutic approach and enhance the value of our CardiAMP cell therapy platform for shareholders and future partners."

07:19 EDT Axsome Therapeutics recognizes May as Mental Health Awareness Month - Axsome Therapeutics is joining the global community of mental health advocates, including Mental Health America, during May's Mental Health Month to raise awareness of the importance of mental health as a key element of overall health. Axsome is committed to the millions of individuals living with mental health conditions, their loved ones, and the healthcare providers involved in their wellness journeys. In support of Mental Health Month and this year's theme of "Where to Start," Axsome is sharing educational resources for those impacted by mental health conditions. "As we enter Mental Health Month this May, we welcome Axsome in joining Mental Health America in promoting awareness, providing vital resources and education, and advocating for the mental health and well-being of all," said Schroeder Stribling, President and CEO, Mental Health America. "This year's theme for Mental Health Month is 'Where to Start: Mental Health in a Changing World.' In a world that is constantly evolving, it can be overwhelming to navigate the various challenges and changes happening around us. The pressures of work, relationships, and societal factors can significantly impact our mental well-being, sometimes even more than we realize. Mental Health America's resources focus on these all-encompassing factors and offer guidance for Where to Start on individuals' own mental health journeys."

07:18 EDT Decisionpoint Systems to be acquired for $10.22 per share in take-private pact - DecisionPoint Systems announced that it entered into a definitive agreement to merge with an affiliate of Barcoding, a portfolio company of Graham Partners, in an all-cash transaction. Under the terms of the agreement, DecisionPoint stockholders will receive $10.22 per share in cash, representing an approximate 27% premium over the closing price of $8.05 on April 30 and a year-to-date return of 63% over the $6.26 per share price on the last trading day of 2023. DecisionPoint's board of directors unanimously approved the merger agreement and recommended that stockholders vote in favor of the merger. The company will send out a proxy and host a special meeting for shareholders to vote on the merger in the near future. The transaction is currently expected to close in July, subject to the approval of DecisionPoint stockholders and the satisfaction of customary closing conditions. Closing of the transaction is not subject to a financing condition. Upon completion of the transaction, DecisionPoint will become a privately held company and its stock will no longer be publicly traded. The company will continue to operate under the DecisionPoint Systems name and brand.

07:17 EDT Widmer Brothers launches new Hefe Variety 12 Pack - Widmer Brothers Brewing is launching a new Hefe Variety 12 Pack, showcasing a wide range of delicious wheat beer style brews. The new Hefe Variety Pack includes the brewery's flagship Hefe along with Imperial Hefe, Widberry Hefe, and Apricot Hefe-expanding the Hefe brand family for the first time since the launch of Imperial Hefe last year.

07:15 EDT OneWater Marine completes acquisition of Garden State Yacht Sales - OneWater Marine announced that it has completed the previously announced acquisition of Garden State Yacht Sales, which further expands the Company's presence in the Mid-Atlantic U.S. and enhances new and pre-owned boat sales, finance, and parts and services offerings. "We would like to thank the Stavola family for the tremendous opportunity to build on Garden State's strong reputation," said Austin Singleton, Chief Executive Officer for OneWater. "The acquisition increases our exposure and expands our suite of offerings in the attractive Mid-Atlantic boating market. Leveraging our proven integration playbook, we expect a seamless transition into the OneWater family of dealers, and we look forward to capitalizing on the strong upside potential of this transaction."

07:12 EDT TG Therapeutics sees FY24 BRIUMVI U.S. revenue approximately $270M-$290M - 2024 Development Pipeline Anticipated Milestones: Commence clinical development of subcutaneous BRIUMVI; Commence a clinical trial evaluating BRIUMVI in an additional autoimmune disease outside of multiple sclerosis; Commence a clinical trial evaluating azer-cel in autoimmune disease; Present data from the ENHANCE Phase 3b CD20 switch trial at multiple conferences throughout the year

07:05 EDT Quest Diagnostics to acquire certain assets of PathAI - Quest Diagnostics and PathAI announced a multi-faceted collaboration designed to accelerate the adoption of digital and AI pathology innovations to improve quality, speed and efficiency in diagnosing cancer and other diseases. Under the terms of a definitive agreement, Quest will acquire select assets of PathAI Diagnostics, the business of PathAI that provides anatomic and digital pathology laboratory services. At closing, PathAI Diagnostics' state-of-the-art digitized laboratory in Memphis, Tennessee will become Quest's AI and digital R&D and solutions center, supporting Quest's specialty pathology businesses, AmeriPath and Dermpath Diagnostics. PathAI will continue to support its biopharmaceutical clients with end-to-end clinical trial services capabilities at its biopharma lab, which is separate and distinct from the diagnostic laboratory business. The transaction is expected to be completed in the second quarter of 2024. Under separate agreements, Quest will license PathAI's AISight digital pathology image management system to support its pathology laboratories and customer sites in the United States. The two entities may also pursue opportunities for Quest to aid PathAI's algorithm product development, drawing on Quest's deep pathology leadership. In addition, Quest will be a preferred provider for PathAI's biopharmaceutical clinical laboratory services.

06:42 EDT Wolverine World Wide enters two global licensing agreements - Wolverine World Wide announced that it has entered into two global licensing agreements as part of its ongoing strategic transformation into a brand-led growth company. Under the first agreement, Vida Shoes International will become the global Merrell and Saucony licensee for kids footwear with rights to these products in almost all markets subject to existing licenses. Vida is one of the Company's key partners, having licensed the Stride Rite brand from Wolverine Worldwide since 2017, and currently sources more than 20 million pair of kids footwear annually in several categories. The company also agreed to license the global rights for Merrell apparel and accessories - including packs, bags, and hats - to Centric Brands LLC in almost all markets subject to existing licenses. Centric has deep licensing experience and currently serves as the apparel and accessories partner for more than 100 global consumer brands. The new partnerships will be managed by Bornie Del Priore, Wolverine Worldwide's President of Global Licensing. Del Priore has decades of licensing experience, including with the company's Hush Puppies and Stride Rite brands and in her prior leadership roles at Tommy Hilfiger and Ralph Lauren.

06:36 EDT G1 Therapeutics reaffirms FY24 guidance - G1 reaffirmed its full year 2024 financial guidance. The company expects to generate between $60 million and $70 million in COSELA net revenue in 2024. G1's product revenue guidance is based on expectations for continued acceleration of sales performance of COSELA in the U.S. Additionally, the company believes that its current cash runway is sufficient to fund its operations into the third quarter of 2025.

06:32 EDT J&J's LLT proposes to resolve all ovarian cancer talc claims via reorganization

06:28 EDT PG&E, KKR enter exclusive talks related to Pacific Generation transaction - Pacific Gas and Electric Company (PCG), PG&E, and KKR (KKR) announce they have entered exclusive talks on a strategic partnership related to its Pacific Generation transaction. As previously announced in September 2022, PG&E is seeking approval to transfer its non-nuclear power generation assets to a newly formed subsidiary, Pacific Generation, and to transfer a minority ownership in Pacific Generation. Under the proposed transactions, PG&E would remain the majority owner of Pacific Generation and the current workforce would continue to operate and maintain the generation facilities for the benefit of customers. "After thoroughly evaluating a full range of potential investors, we believe that a strategic partnership with KKR would be highly beneficial to our customers by supporting investment in generation and storage assets that are critical contributors to clean, reliable energy, and providing a path to lower rates," said Carolyn Burke, Executive Vice President and Chief Financial Officer at PG&E. "As we continue to build our systems, we must accelerate the infrastructure investments that will enable us to provide our customers with safe, sustainable, reliable, and affordable energy. With a strong strategic partner like KKR, we would be better positioned to help support cleaner energy generation, such as hydro and pumped storage, as well as other energy storage assets needed to balance California's portfolio of intermittent renewable resources and mitigate wholesale market volatility."

06:22 EDT Brown-Forman completes sale of Sonoma-Cutrer Vineyards to Duckhorn Portfolio - Brown-Forman (BFA, BFB) announced that it completed the sale of Sonoma-Cutrer Vineyards and related brand trademarks to The Duckhorn Portfolio (NAPA) on April 30. In November 2023, Brown-Forman disclosed it had reached an agreement to sell the brand in exchange for an ownership percentage of approximately 21.5% in The Duckhorn Portfolio and $50M. As part of the agreement, The Duckhorn Portfolio has named two Brown-Forman executives to its Board of Directors, Marshall Farrer, Chief Strategic Growth Officer, and Tim Nall, Chief Global Supply Chain and Technology Officer. Under the terms of the agreement, the Sonoma-Cutrer brand trademarks, facilities, and six vineyards in two appellations will join The Duckhorn Portfolio's luxury wine brands.

06:12 EDT Duckhorn Portfolio names Deirdre Mahlan as CEO - The Duckhorn Portfolio (NAPA) announced that Deirdre Mahlan has been appointed President, CEO and Chairperson, effective immediately. Mahlan has been a member of The Duckhorn Portfolio Board of Directors since March 2021. For the past six months, she has served as interim President, CEO and Chairperson, during which time the Board conducted an internal and external leadership search and determined that Mahlan is best positioned to lead the company forward. Mahlan brings over 30 years of alcohol and beverage industry experience and an extensive track record of operational and financial leadership. Previously, she spent 20 years at Diageo (DEO), most recently serving as President of Diageo North America.

06:09 EDT High Tide names Mayank Mahajan CFO - High Tide announced that Mayank Mahajan has joined the company in the role of CFO.

06:08 EDT Landsea Homes sees Q2 new home deliveries 600-650 - Q2 delivery ASPs expected to be in the range of $525,000 to $530,000; Home sales gross margin to be between 15% and 16%.

05:33 EDT Nio delivers 15,620 vehicles in April, up 134.6% - Nio announced its April delivery results. Nio delivered 15,620 vehicles in April, representing a strong increase of 134.6% year-over-year. The deliveries consisted of 8,817 premium smart electric SUVs, and 6,803 premium smart electric sedans. Cumulative deliveries of Nio vehicles reached 495,267 as of April 30. On April 25, Nio launched its 2024 ET7, a smart electric executive sedan. Deliveries of the 2024 ET7 began on April 30. On April 25, Nio entered into a strategic cooperation with Lotus Technology, a global luxury electric vehicle maker, on charging and swapping.

05:18 EDT Li Auto delivers 25,787 vehicles in April, up 0.4% - Li Auto announced that the company delivered 25,787 vehicles in April, up 0.4% year over year. The cumulative deliveries of Li Auto vehicles reached 739,551 as of the end of April. As of April 30, the company had 481 retail stores in 144 cities, as well as 361 servicing centers and Li Auto-authorized body and paint shops operating in 210 cities. 386 super charging stations have commenced operation across the country, equipped with 1,678 charging stalls.

05:12 EDT Vertical CEO Stephen Fitzpatrick transitions to board, Stuart Simpson to succeed - Vertical Aerospace has made several leadership appointments as the company moves towards a pivotal phase of certifying its VX4 aircraft and commercialization. Stuart Simpson, Vertical's CFO, has been appointed to CEO, effective immediately. He will be responsible for leading the execution of the company's strategy as it progresses towards certification of the VX4 aircraft, bringing it to market, and launching further fundraising activity. Founder and current CEO, Stephen Fitzpatrick, who recently committed additional capital to the company, will continue to play a prominent role in Vertical as a board member, focused on business strategy and working with the executive team to deliver on the company's vision.